Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising/recruitment
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All...
  • Videos
  • Collections
    • Recently published
    • Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • About
  • Editors
  • Consulting Editors
  • For authors
  • Transfers
  • Current issue
  • Past issues
  • By specialty
  • Contact
  • Recently published
  • Technical Advances
  • Clinical Medicine
  • Editorials
  • Top read articles
Tyro3 is a podocyte protective factor in glomerular disease
Fang Zhong, … , Zhihong Liu, John Cijiang He
Fang Zhong, … , Zhihong Liu, John Cijiang He
Published November 15, 2018
Citation Information: JCI Insight. 2018;3(22):e123482. https://doi.org/10.1172/jci.insight.123482.
View: Text | PDF
Categories: Research Article Nephrology

Tyro3 is a podocyte protective factor in glomerular disease

  • Text
  • PDF
Abstract

Our previous work demonstrated a protective role of protein S in early diabetic kidney disease (DKD). Protein S exerts antiinflammatory and antiapoptotic effects through the activation of TYRO3, AXL, and MER (TAM) receptors. Among the 3 TAM receptors, we showed that the biological effects of protein S were mediated largely by TYRO3 in diabetic kidneys. Our data now show that TYRO3 mRNA expression is highly enriched in human glomeruli and that TYRO3 protein is expressed in podocytes. Interestingly, glomerular TYRO3 mRNA expression increased in mild DKD but was suppressed in progressive DKD, as well as in focal segmental glomerulosclerosis (FSGS). Functionally, morpholino-mediated knockdown of tyro3 altered glomerular filtration barrier development in zebrafish larvae, and genetic ablation of Tyro3 in murine models of DKD and Adriamycin-induced nephropathy (ADRN) worsened albuminuria and glomerular injury. Conversely, the induction of TYRO3 overexpression specifically in podocytes significantly attenuated albuminuria and kidney injury in mice with DKD, ADRN, and HIV-associated nephropathy (HIVAN). Mechanistically, TYRO3 expression was suppressed by activation of TNF-α/NF-κB pathway, which may contribute to decreased TYRO3 expression in progressive DKD and FSGS, and TYRO3 signaling conferred antiapoptotic effects through the activation of AKT in podocytes. In conclusion, TYRO3 plays a critical role in maintaining normal podocyte function and may be a potential new drug target to treat glomerular diseases.

Authors

Fang Zhong, Zhaohong Chen, Liwen Zhang, Yifan Xie, Viji Nair, Wenjun Ju, Matthias Kretzler, Robert G. Nelson, Zhengzhe Li, Hongyu Chen, Yongjun Wang, Aihua Zhang, Kyung Lee, Zhihong Liu, John Cijiang He

×

Figure 6

Global KO of Tyro3 increases podocyte foot process effacement and loss in ADRN mice.

Options: View larger image (or click on image) Download as PowerPoint
Global KO of Tyro3 increases podocyte foot process effacement and loss i...
(A) Representative transmission EM images of control and ADRN mice at 2,000× (×2k) and 10,000× (×10k) magnifications. Scale bar: 5 μm. (B) Quantification of foot process width (nm) in control and ADRN mice. One-tailed, paired t test. (C) Quantitative PCR analysis of WT1 mRNA in isolated glomeruli from control and ADRN mice. (D) Representative images WT1 immunofluorescence. Scale bar: 20 µm. (E) Number of WT1+ cells per 1,000 μm2 glomerular tuft area. Data are shown as mean ± SEM; n = 6 in each group; statistical analysis was performed with 1-way ANOVA with Tukey’s multiple comparison test; **P < 0.01 and ****P < 0.0001 when compared with vehicle-injected control mice; #P < 0.05 and ##P < 0.01 when compared with WT-ADR.
Follow JCI Insight:
Copyright © 2019 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts